Unique Wealth LLC Buys 92 Shares of Cencora, Inc. (NYSE:COR)

Unique Wealth LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 7.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,385 shares of the company’s stock after buying an additional 92 shares during the quarter. Unique Wealth LLC’s holdings in Cencora were worth $311,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in COR. LPL Financial LLC boosted its position in Cencora by 6.3% during the second quarter. LPL Financial LLC now owns 164,327 shares of the company’s stock worth $37,023,000 after purchasing an additional 9,697 shares during the period. BOKF NA boosted its position in Cencora by 106.0% during the second quarter. BOKF NA now owns 2,200 shares of the company’s stock worth $496,000 after purchasing an additional 1,132 shares during the period. Parallel Advisors LLC boosted its position in Cencora by 6.4% during the second quarter. Parallel Advisors LLC now owns 4,961 shares of the company’s stock worth $1,118,000 after purchasing an additional 299 shares during the period. Oppenheimer Asset Management Inc. boosted its position in Cencora by 2.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 28,452 shares of the company’s stock worth $6,410,000 after purchasing an additional 616 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Cencora by 4.2% during the second quarter. Envestnet Asset Management Inc. now owns 560,450 shares of the company’s stock worth $126,269,000 after purchasing an additional 22,735 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.0 %

Shares of Cencora stock opened at $236.10 on Tuesday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27. The stock has a market capitalization of $45.63 billion, a price-to-earnings ratio of 31.44, a P/E/G ratio of 1.54 and a beta of 0.49. The company’s 50 day moving average price is $237.82 and its 200-day moving average price is $233.54.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.93%. Cencora’s dividend payout ratio is currently 29.29%.

Analysts Set New Price Targets

A number of brokerages have weighed in on COR. Robert W. Baird increased their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI increased their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Bank of America reissued a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $275.60.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 in the last three months. 15.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.